Found: 35
Select item for more details and to access through your institution.
Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 2, p. 145, doi. 10.1007/s40256-022-00557-2
- By:
- Publication type:
- Article
Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.
- Published in:
- Pulmonary Circulation, 2019, v. 9, n. 2, p. N.PAG, doi. 10.1177/2045894019848644
- By:
- Publication type:
- Article
Population pharmacokinetics of single-dose riociguat in patients with renal or hepatic impairment.
- Published in:
- Pulmonary Circulation, 2016, v. 6, p. S75, doi. 10.1086/685647
- By:
- Publication type:
- Article
Pharmacokinetic interaction study between riociguat and the combined oral contraceptives levonorgestrel and ethinylestradiol in healthy postmenopausal women.
- Published in:
- Pulmonary Circulation, 2016, v. 6, p. S97, doi. 10.1086/685428
- By:
- Publication type:
- Article
Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
- Published in:
- Pulmonary Circulation, 2016, v. 6, p. S86, doi. 10.1086/685404
- By:
- Publication type:
- Article
Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food.
- Published in:
- Pulmonary Circulation, 2016, v. 6, p. S66, doi. 10.1086/685020
- By:
- Publication type:
- Article
Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
- Published in:
- Pulmonary Circulation, 2016, v. 6, p. S58, doi. 10.1086/685019
- By:
- Publication type:
- Article
Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
- Published in:
- Pulmonary Circulation, 2016, v. 6, p. S15, doi. 10.1086/685017
- By:
- Publication type:
- Article
Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality.
- Published in:
- Pulmonary Circulation, 2016, v. 6, p. S27, doi. 10.1086/685018
- By:
- Publication type:
- Article
Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolam.
- Published in:
- Pulmonary Circulation, 2016, v. 6, p. S49, doi. 10.1086/685016
- By:
- Publication type:
- Article
Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
- Published in:
- Pulmonary Circulation, 2016, v. 6, p. S5, doi. 10.1086/685015
- By:
- Publication type:
- Article
Effects of omeprazole and aluminum hydroxide/magnesium hydroxide on riociguat absorption.
- Published in:
- Pulmonary Circulation, 2016, v. 6, p. S43, doi. 10.1086/682228
- By:
- Publication type:
- Article
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Absorption behavior of riociguat: bioavailability, food effects, and dose-proportionality.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Effects of omeprazole and AlOH/MgOH on riociguat absorption.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects.
- Published in:
- European Journal of Clinical Pharmacology, 2021, v. 77, n. 4, p. 527, doi. 10.1007/s00228-020-03023-7
- By:
- Publication type:
- Article
Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 6, p. 751, doi. 10.1007/s40262-024-01384-1
- By:
- Publication type:
- Article
Authors' Reply to Ganijee et al.: "Comment on: Evaluation of the Influence of Sildenafil on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults".
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 11, p. 1651, doi. 10.1007/s40262-023-01304-9
- By:
- Publication type:
- Article
Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches.
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 11, p. 1639, doi. 10.1007/s40262-023-01282-y
- By:
- Publication type:
- Article
Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults.
- Published in:
- Clinical Pharmacokinetics, 2023, v. 62, n. 2, p. 321, doi. 10.1007/s40262-022-01203-5
- By:
- Publication type:
- Article
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
- Published in:
- Clinical Pharmacokinetics, 2021, v. 60, n. 11, p. 1407, doi. 10.1007/s40262-021-01024-y
- By:
- Publication type:
- Article
Results from in vitro and in vivo studies evaluating the bioavailability, effects of food, and administration as crushed tablet suspension on vericiguat pharmacokinetics.
- Published in:
- AAPS Open, 2022, v. 8, n. 1, p. 1, doi. 10.1186/s41120-022-00063-4
- By:
- Publication type:
- Article
Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers.
- Published in:
- Clinical Pharmacokinetics, 2021, v. 60, n. 3, p. 337, doi. 10.1007/s40262-020-00935-6
- By:
- Publication type:
- Article
Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies.
- Published in:
- Clinical Pharmacokinetics, 2020, v. 59, n. 11, p. 1407, doi. 10.1007/s40262-020-00895-x
- By:
- Publication type:
- Article
Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban.
- Published in:
- Clinical Pharmacokinetics, 2014, v. 53, n. 1, p. 89, doi. 10.1007/s40262-013-0090-5
- By:
- Publication type:
- Article
Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 5, p. 1061, doi. 10.1002/cpt.2712
- By:
- Publication type:
- Article
Vericiguat in Combination with Short‐Acting Nitroglycerin in Patients With Chronic Coronary Syndromes: The Randomized, Phase Ib, VENICE Study.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 6, p. 1239, doi. 10.1002/cpt.2574
- By:
- Publication type:
- Article
Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 1, p. 79, doi. 10.1002/psp4.13059
- By:
- Publication type:
- Article
No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of ricochet (BAY 63-2521) and aspirin.
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 5, p. 1204, doi. 10.1111/cts.13238
- By:
- Publication type:
- Article